上市后藥物經濟學評價方法Ⅲ：影響方法學質量和結果可適用性的因素_《中國循證醫學雜志》

作者：

孫鑫 ¹ , 李幼平 ¹ , Thomas Alured Faunce ² , 程剛 ³

1. 四川大學華西醫院循證醫學與臨床流行病學研究中心（成都 610041） 2. 澳大利亞國立大學，醫學院和法律學院 3. 國家食品與藥品監督管理局藥物評價中心（北京 100061）;

關鍵詞：

社會經濟學評價成本-效果評價上市后藥物經濟價值方法學質量結果外在適用性

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

方法學質量和結果可適用性是評價已發表藥物經濟學評價研究可靠性和適用性的重要方面，也是影響我國上市后藥物社會經濟價值評價的因素。本文探討了經濟學評價研究中影響方法學質量和結果可適用性的因素及其方式，并特別強調了在我國條件下的影響因素。本文討論了經濟學評價合理的設計、實施和分析和報道方法，并介紹了現有評價經濟學研究方法學質量量表中，兩種適用于我國的評價量表。

引用本文： 孫鑫,李幼平,Thomas Alured Faunce,程剛. 上市后藥物經濟學評價方法Ⅲ：影響方法學質量和結果可適用性的因素. 中國循證醫學雜志, 2006, 06(4): 282-291. doi: 復制

1.	Salkeld F, Davey P, Arnolda G. A critical review of health-related economic evaluation in Australia: implications for health policy. Health Policy, 1995;31:111-125.
2.	Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc. Sci. Med,1997;45(4):563-581.
3.	Garceau L, Henderson J, Davis LJ, et al. Davidson LL. Economic implications of assisted reproductive techniques: a systematic review. Human reproduction, 2002;17(12):3090-3109.
4.	Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ, 2000;321;659-664.
5.	Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA, 2002;287:2809-2812.
6.	Sulpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess, 2004;8(49).
7.	Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more trans fer able? Eur J Health Econom, 2005, 6:334–346.
8.	Drummond MF, Jefferson TO. On behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996;313:275-283.
9.	Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
10.	National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence Handbook series on preparing clinical practice Guidelines. Commonwealth of Australia, 2000.
11.	Green C, Brazier J, Deverill M. Valuing Health-Related Quality of Life. A Review of Health State Valuation Techniques. Pharmacoeconomics, 2000; 17 (2): 151-165.
12.	Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics, 2002; 20 (7): 443-454.
13.	Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics, 1997; 6: 217–227.
14.	Birkett DJ, Mitchell AS, McManus P. A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Affairs, 2001; 20(3): 104-114.
15.	Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care, 1992;30:231–238.
16.	Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ Economic Evaluation Working Party. BMJ, 1996;313:275–283.
17.	Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health. 1996. Oxford, Oxford University Press.
18.	Nixon J, Pang F. Economic evaluations in Japan: a review of published studies, methodological issues and practice. In: Kondo S, Furuta K (eds) 2000 PSAM 5 – probabilistic safety assessment and management, vol 3. Universal Academy: Tokyo, pp 2077–2084.
19.	Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care, 2005;21(2):240–245.
20.	Shannon S. Critical appraisal of economic analysis studies. Can Assoc Rodiol J, 2002;53(5):251-4.
21.	Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
22.	Chiou CF, Hay JW, Wallace JF, et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003;41(1):32-44.
23.	Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econom, 2002;3:131–136.
24.	Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. Journal of Gastroenterology and Hepatology, 2002; 17:153–164.

1. Salkeld F, Davey P, Arnolda G. A critical review of health-related economic evaluation in Australia: implications for health policy. Health Policy, 1995;31:111-125.
2. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc. Sci. Med,1997;45(4):563-581.
3. Garceau L, Henderson J, Davis LJ, et al. Davidson LL. Economic implications of assisted reproductive techniques: a systematic review. Human reproduction, 2002;17(12):3090-3109.
4. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ, 2000;321;659-664.
5. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA, 2002;287:2809-2812.
6. Sulpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess, 2004;8(49).
7. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more trans fer able? Eur J Health Econom, 2005, 6:334–346.
8. Drummond MF, Jefferson TO. On behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996;313:275-283.
9. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
10. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence Handbook series on preparing clinical practice Guidelines. Commonwealth of Australia, 2000.
11. Green C, Brazier J, Deverill M. Valuing Health-Related Quality of Life. A Review of Health State Valuation Techniques. Pharmacoeconomics, 2000; 17 (2): 151-165.
12. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics, 2002; 20 (7): 443-454.
13. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics, 1997; 6: 217–227.
14. Birkett DJ, Mitchell AS, McManus P. A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Affairs, 2001; 20(3): 104-114.
15. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care, 1992;30:231–238.
16. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ Economic Evaluation Working Party. BMJ, 1996;313:275–283.
17. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health. 1996. Oxford, Oxford University Press.
18. Nixon J, Pang F. Economic evaluations in Japan: a review of published studies, methodological issues and practice. In: Kondo S, Furuta K (eds) 2000 PSAM 5 – probabilistic safety assessment and management, vol 3. Universal Academy: Tokyo, pp 2077–2084.
19. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care, 2005;21(2):240–245.
20. Shannon S. Critical appraisal of economic analysis studies. Can Assoc Rodiol J, 2002;53(5):251-4.
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
22. Chiou CF, Hay JW, Wallace JF, et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003;41(1):32-44.
23. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econom, 2002;3:131–136.
24. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. Journal of Gastroenterology and Hepatology, 2002; 17:153–164.

《中國循證醫學雜志》

上市后藥物經濟學評價方法Ⅲ：影響方法學質量和結果可適用性的因素

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

上市后藥物經濟學評價方法Ⅲ：影響方法學質量和結果可適用性的因素

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料